Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue

About this update from Organogenesis Holdings Inc.

[{"type":"image","alt":"Organogenesis Holdings Inc.","displaySize":"","headline":null,"caption":"Organogenesis Holdings Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":27,"url":"https://media.zenfs.com/en/globenewswire.com/3509a450a351739b6cff62eb8ef9574f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dgKHRo3RxqU3brFgDz5L5g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/3509a450a351739b6cff62eb8ef9574f","width":300,"height":27}},"lazy":false},{"type":"text","content":"CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2025.","length":416,"tagName":"p"},{"type":"text","content":"Fourth Quarter 2025 Financial Results Summary:","length":46,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net product revenue of $225.1 million for the fourth quarter of 2025, an increase of $98.4 million compared to net product revenue of $126.7 million for the fourth quarter of 2024. Net product revenue for the fourth quarter of 2025 consists of:","length":244,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net product revenue from Advanced Wound Care products of $217.2 million, an increase of 83% from the fourth quarter of 2024.","length":124,"tagName":"p"}]},{"val":[{"type":"text","content":"Net product revenue from Surgical & Sports Medicine products of $7.9 million, a decrease of 2% from the fourth quarter of 2024.","length":131,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":255,"olType":false}]},{"val":[{"type":"text","content":"Net income of $43.7 million for the fourth quarter of 2025, compared to net income of $7.7 million for the fourth quarter of 2024, an increase in net income of $36.0 million.","length":174,"tagName":"p"}]},{"val":[{"type":"text","content":"Adjusted EBITDA of $84.2 million for the fourth quarter of 2025, compared to Adjusted EBITDA of $18.2 million for the fourth quarter of 2024, an increase of $66.0 million.","length":171,"tagName"...

More updates from Organogenesis Holdings Inc.